Investigating potential mediator between statin and coronary artery calcification

PLoS One. 2018 Sep 18;13(9):e0203702. doi: 10.1371/journal.pone.0203702. eCollection 2018.

Abstract

Statins are mainstay anti-lipidaemic treatments for preventing cardiovascular diseases but also known to increase coronary artery calcification (CAC). However, underlying relationship between statin and CAC is still unclear. This study explored the mediating role of five statin-related biochemical factors [i.e., low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, triglyceride, glucose, and high sensitivity C-reactive protein levels]. Seoul Metabolic Syndrome cohort study includes 1370 participants suspected of metabolic syndrome. For causal mediation analysis, the dataset for 2016 including 847 participants with coronary computed tomography without any missing value were analysed using the Mediation package in R software. This study identified a causal mediation mechanism of HDL-cholesterol among the five biochemical factors. It implied that statin treatment increases the HDL-cholesterol level, leading to decreasing the probability of CAC score > 0. Estimated values of interest in HDL-cholesterol mediation were (1) average causal mediation effect, -0.011 with 95% CI [-0.025, -0.003], (2) average direct effect, 0.143 with 95% CI [0.074, 0.219], and total effect, 0.132 with 95% CI [0.063, 0.209]. Its mediation effect was maintained regardless of statin intensity. Sensitivity analysis also provided a robustness of the results under potential existence of a confounder between HDL-cholesterol and CAC. This study suggests a potential causal pathway between statin and CAC (the positive association of statin on CAC) through HDL-cholesterol as an inhibitor.

Trial registration: ClinicalTrials.gov NCT02077530.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose
  • C-Reactive Protein / metabolism
  • Calcinosis / chemically induced*
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Cohort Studies
  • Coronary Artery Disease / pathology*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Joint Diseases / chemically induced*
  • Republic of Korea
  • Triglycerides / blood
  • Vascular Diseases / chemically induced*

Substances

  • Blood Glucose
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Triglycerides
  • C-Reactive Protein

Supplementary concepts

  • Calcification of Joints and Arteries

Associated data

  • ClinicalTrials.gov/NCT02077530

Grants and funding

This research was supported by a Korea University Grant and a grant from the Seoul Metropolitan Government. This study is registered at www.clinicaltrials.gov (NCT02077530). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.